RUBY News
Archived Headlines
- Red Blood Cell Therapies: Worth $2 Billion or $200 Million? 07/11/18
- The IPO market has resumed being on fire with 11 new deals 07/10/18
- Red blood cell biotech Rubius Therapeutics sets terms for $200 million IPO 07/09/18
- US IPO Week Ahead: No IPOs expected, but over 10 deals could launch 07/06/18
- US IPO Week Ahead: No IPOs in the short holiday week 06/29/18
See more
No trial, no problem: Biggest week for preclinical biotech IPOs ever
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more
US IPO Weekly Recap: Bud, biotechs, banks and breast implants make gains in 9-IPO week
The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more
Superblood biotech Rubius Therapeutics prices upsized IPO above the range at $23
Rubius Therapeutics, a preclinical biotech developing novel therapies based on red blood cells, raised $241 million by offering 10.5 million shares at $23, above the $20 to $22 range. The company had originally planned to raise $200 million by selling 9.5...read more
US IPO Week Ahead: 10 US IPOs planned for the week of July 16
There are 10 IPOs expected to price this week after the July holiday slowdown. The week is being led by oil and gas OEM AFG Holdings and Canadian cannabis supplier Tilray. Six...read more